Novo, Bayer, Ramaswamy, CellCentric: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Novo Nordisk (NVO) Q1 2026 earnings: Wegovy sales jump
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in…
FDA proposes excluding Novo, Lilly GLP-1s from compounding list
The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed…
Europe’s first sweet protein facility begins in Vilnius
The factory is expected to begin operations in the first half of 2027. “Lithuania is consistently strengthening its…
KRAS, Novo Nordisk, Eli Lilly, Kelonia: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Why Orbán’s man in Brussels is here to stay — for now – POLITICO
… easier to freeze out Ultimately, whether Várhelyi continues to hold sway in the Berlaymont is largely in…
Novo Nordisk’s Wegovy pill launch draws new wave of patients to GLP-1s
After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work…
Novo Nordisk Wegovy, Medicare Advantage: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Eli Lilly’s obesity pill approved by FDA, setting up competition with Novo Nordisk
Eli Lilly’s obesity pill was approved by the Food and Drug Administration on Wednesday, setting it up for…
Novo Nordisk, Orca Bio, FDA, Novartis: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Novo Nordisk launches Wegovy subscription for GLP-1 obesity drugs
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images Novo Nordisk on Tuesday launched a…
Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
Novo Nordisk A/S UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G),…